Literature DB >> 16911693

Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.

Hiroyuki Kaneda1, Etsuko Hashimoto, Satoru Yatsuji, Katsutoshi Tokushige, Keiko Shiratori.   

Abstract

BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of liver disease from simple steatosis to cirrhosis. Therefore, markers for predicting NAFLD with advanced fibrosis are needed. The aim of this study was to establish non-invasive predictive markers of liver fibrosis in NAFLD.
METHODS: One hundred and forty-eight patients were diagnosed as having biopsy-proven NAFLD. In order to separately identify severe fibrosis (bridging fibrosis plus cirrhosis) and cirrhosis, the patients were analyzed twice: first, as mild fibrosis versus severe fibrosis; and second, as non-cirrhosis versus cirrhosis. Univariate and multivariate analyses were conducted. The diagnostic ability to detect severe fibrosis and cirrhosis was assessed by the area under the receiver operating characteristic curve. The cut-off values of serum markers to detect severe fibrosis and cirrhosis were determined.
RESULTS: Hyaluronic acid was selected as a predictive marker for severe fibrosis. A cut-off value of 42 ng/mL of hyaluronic acid had a 100% predictive value for patients free of severe fibrosis and was associated with an optimal combination of sensitivity (100%, 95% confidence interval [CI] 90-100%) and specificity (89%, 95%CI 80-94%). The platelet count was found to be an independent predictor of cirrhosis. A cut-off value of 16 x 10(4)/microL for the platelet count was associated with an optimal combination of sensitivity (100%, 95%CI 82-100%) and specificity (95%, 95%CI 90-98%).
CONCLUSIONS: Hyaluronic acid levels can accurately identify NAFLD patients with severe fibrosis, and the platelet count can identify NAFLD patients with cirrhosis. Thus, these markers offer a good guideline for the assessment of hepatic fibrosis in the many patients with NAFLD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16911693     DOI: 10.1111/j.1440-1746.2006.04447.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  39 in total

Review 1.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Platelet count for predicting fibrosis in nonalcoholic fatty liver disease.

Authors:  Masato Yoneda; Hideki Fujii; Yoshio Sumida; Hideyuki Hyogo; Yoshito Itoh; Masafumi Ono; Yuichiro Eguchi; Yasuaki Suzuki; Noriaki Aoki; Kazuyuki Kanemasa; Kento Imajo; Kazuaki Chayama; Toshiji Saibara; Norifumi Kawada; Kazuma Fujimoto; Yutaka Kohgo; Toshikazu Yoshikawa; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2011-07-13       Impact factor: 7.527

3.  Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis.

Authors:  Shotaro Naganawa; Kenichiro Enooku; Ryosuke Tateishi; Hiroyuki Akai; Koichiro Yasaka; Junji Shibahara; Tetsuo Ushiku; Osamu Abe; Kuni Ohtomo; Shigeru Kiryu
Journal:  Eur Radiol       Date:  2018-02-05       Impact factor: 5.315

Review 4.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 5.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

6.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

7.  Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis.

Authors:  Kento Imajo; Masato Yoneda; Koji Fujita; Takaomi Kessoku; Wataru Tomeno; Yuji Ogawa; Yoshiyasu Shinohara; Yusuke Sekino; Hironori Mawatari; Yuichi Nozaki; Hiroyuki Kirikoshi; Masataka Taguri; Gen Toshima; Junichiro Takahashi; Satoru Saito; Koichiro Wada; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2013-03-16       Impact factor: 7.527

Review 8.  NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?

Authors:  Shivaram P Singh; Rakesh K Barik
Journal:  J Clin Exp Hepatol       Date:  2019-09-21

9.  Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.

Authors:  Anil Arora; Praveen Sharma
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

Review 10.  Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Pharmaceut Med       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.